At Retina Specialty Institute, we are recognized nationally for our participation in clinical trials and for giving our patients access to the most advanced care. We choose this path of innovation not because it is easy, but because we hold steadfastly to a vision of treating and of, someday, curing patients.
The field of retina has evolved tenfold over the past decade. This progress only fuels our desire to do more, to forge ahead, and to break out on behalf of our patients.
As a national, randomized, FDA approved clinical trial study center, Retina Specialty Institute has earned its reputation among major pharmaceutical companies, peers, and patients by delivering peak performance time and time again.
Our deep and vast experience, staff certification, high-level instrumentation, ability to recruit and retain patients, proven record of capturing data effectively, and our diligence are at the core of success in a competitive, carefully screened research field.
Retina Specialty Institute has participated in clinical trials for Age-Related Wet Macular Degeneration (Wet AMD), Diabetic Retinopathy (DME), Retinal Vein Occlusion (BRVO/CRVO), and Vitromacular Traction Syndrome (VMT), which are all leading causes of blindness. Our goal is, through research, to provide patients with better results while being less intrusive. For more information on RSI’s involvement in national clinical trials, check out our list of RSI clinical trials.
Retina Specialty Institute is proud to be among the top national sites for clinical trials. Our commitment to research is continuously strengthened as we recognize the increased benefits for our patients. While not every patient is a candidate, everyone benefits from what we learn. The more we know, the closer we come to realizing our vision of curing all.
To learn more about clinical trials, please visit http://www.clinicaltrials.gov.